CR10228A - Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina - Google Patents

Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina

Info

Publication number
CR10228A
CR10228A CR10228A CR10228A CR10228A CR 10228 A CR10228 A CR 10228A CR 10228 A CR10228 A CR 10228A CR 10228 A CR10228 A CR 10228A CR 10228 A CR10228 A CR 10228A
Authority
CR
Costa Rica
Prior art keywords
antiaterotrombotic
association
inhibitor
conversion enzyme
angiotensin conversion
Prior art date
Application number
CR10228A
Other languages
English (en)
Inventor
Verbeuren Tony
Sansilvestri-Morel Patricia
Rupin Alain
Vallez Marie-Odilie
Frataccif Marie-Dominique
Lerond Laurence
La Vielle Gilber
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of CR10228A publication Critical patent/CR10228A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Asociación de un antiaterotrombótico y de un inhibidor de la enzima de conversión de la angiotensina (IECA), así como las composiciones farmacéuticas que la contienen.
CR10228A 2007-09-11 2008-08-20 Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina CR10228A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706345A FR2920772B1 (fr) 2007-09-11 2007-09-11 Association entre un anti-atherothrombotique et un inhibiteur de l'enzyme de conversion de l'angiotensine

Publications (1)

Publication Number Publication Date
CR10228A true CR10228A (es) 2009-04-28

Family

ID=39366989

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10228A CR10228A (es) 2007-09-11 2008-08-20 Asociacion entre un antiaterotrombotico y un inhibidor de la enzima de conversion de la angiotensina

Country Status (27)

Country Link
US (1) US20090075976A1 (es)
EP (1) EP2036886A1 (es)
JP (1) JP2009067793A (es)
KR (1) KR20090027167A (es)
CN (1) CN101385723A (es)
AP (1) AP2008004590A0 (es)
AR (1) AR068385A1 (es)
AU (1) AU2008207584A1 (es)
BR (1) BRPI0804140A2 (es)
CA (1) CA2638354A1 (es)
CL (1) CL2008002653A1 (es)
CO (1) CO6020018A1 (es)
CR (1) CR10228A (es)
EA (1) EA200801829A1 (es)
EC (1) ECSP088713A (es)
FR (1) FR2920772B1 (es)
GT (2) GT200800169A (es)
IL (1) IL193585A0 (es)
MA (1) MA30374B1 (es)
MX (1) MX2008011329A (es)
NZ (1) NZ571144A (es)
PA (1) PA8795401A1 (es)
PE (1) PE20090941A1 (es)
SG (1) SG151171A1 (es)
TW (1) TW200920354A (es)
UY (1) UY31304A1 (es)
WO (1) WO2009066035A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012015944A2 (en) * 2010-07-29 2012-02-02 The Trustees Of The University Of Pennsylvania Novel tetrahydronaphalene antagonists to the thromboxane a2 (tp) receptor
CN109248319A (zh) * 2017-07-14 2019-01-22 郜建敏 含有司坦类化合物和阿司匹林的药物组合物
EP3853200B1 (en) 2018-09-18 2024-01-24 Eli Lilly and Company Erbumine salt of treprostinil

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2711139B1 (fr) * 1993-10-15 1995-12-01 Adir Nouveaux dérivés de 1,2,3,4-tétrahydronaphtalène, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US6509348B1 (en) * 1998-11-03 2003-01-21 Bristol-Myers Squibb Company Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination
FR2838057B1 (fr) * 2002-04-05 2005-07-08 Servier Lab Nouvelle association d'un antithrombotique et d'aspirine
FR2857593B1 (fr) * 2003-07-18 2005-10-14 Servier Lab Composition pharmaceutique orodispersible d'un compose antithrombotique
FR2860436B1 (fr) * 2003-10-03 2006-01-20 Servier Lab Nouvelle association d'un anti-atherothrombotique et d'un antiagregant plaquettaire
FR2894825B1 (fr) * 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent

Also Published As

Publication number Publication date
IL193585A0 (en) 2011-08-01
UY31304A1 (es) 2008-09-30
PE20090941A1 (es) 2009-07-18
JP2009067793A (ja) 2009-04-02
FR2920772A1 (fr) 2009-03-13
MX2008011329A (es) 2009-03-10
KR20090027167A (ko) 2009-03-16
CO6020018A1 (es) 2009-03-31
US20090075976A1 (en) 2009-03-19
CL2008002653A1 (es) 2009-06-05
AP2008004590A0 (en) 2008-08-31
CA2638354A1 (fr) 2009-03-11
ECSP088713A (es) 2008-10-31
SG151171A1 (en) 2009-04-30
CN101385723A (zh) 2009-03-18
NZ571144A (en) 2010-01-29
PA8795401A1 (es) 2009-04-23
FR2920772B1 (fr) 2009-10-23
WO2009066035A3 (fr) 2009-08-27
MA30374B1 (fr) 2009-05-04
EA200801829A1 (ru) 2009-06-30
AU2008207584A1 (en) 2009-03-26
TW200920354A (en) 2009-05-16
GT200800178A (es) 2010-07-02
WO2009066035A2 (fr) 2009-05-28
BRPI0804140A2 (pt) 2009-06-16
EP2036886A1 (fr) 2009-03-18
GT200800169A (es) 2010-05-21
AR068385A1 (es) 2009-11-11

Similar Documents

Publication Publication Date Title
UA104459C2 (uk) Антитіла проти fgfr3 і способи їх застосування
JO2778B1 (en) Certain Compounds, Compositions and Methods
MX2010004674A (es) Variantes de alfa-amilasa con propiedades alteradas.
CL2016002589A1 (es) Uso del compuesto genz-112638 (eliglustat), inhibidor de glucosilceramida sintasa, en el tratamiento de la enfermedad de gaucher y enfermedad de fabry (divisional de solicitud 201201348).
CL2011002857A1 (es) Compuestos derivados de fenil o heteroaril piridina, inhibidores de sintasa de aldosterona; composicion farmaceutica que comprende un compuesto; combinacion farmaceutica que comprende un compuesto; y uso de los compuestos en el tratamiento de enfermedades cardiovasculares.
ECSP088759A (es) Composiciones farmacéuticas
BRPI0917017B8 (pt) inibidores de pirrol de s-nitrosoglutationa redutase como agentes terapêuticos
CL2007002182S1 (es) Terminal.
UY31273A1 (es) Fenilendiaminas sustituidas como inhibidores de la interaccion entre mdm2 y p53
EA200701918A1 (ru) Белок липокалин
NO20082298L (no) Kaliumkanalinhibitorer
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
CO6241120A2 (es) (DIHIDRO)PIRROLO[2,1-á]ISOQUINOLINAS.
EP2129672A4 (en) ESTER AND CARBAMATE AZAADAMANTANE DERIVATIVES AND METHODS OF USE
PA8667201A1 (es) Nuevos compuestos farmaceuticos
WO2010141833A3 (en) Vital fluorochrome conjugates and methods of use
ECSP088476A (es) Combinación de productos activos fungicidas
IN2012DN01379A (es)
ECSP088713A (es) Asociación entre un antiaterotrombótico y un inhibidor de la enzima de conversión de la angiotensina
NO20091386L (no) Fenyloksyanilinderivater
NI201000139A (es) ASOCIACION DE UN INHIBIDOR DE CORRIENTE SINUSAL If Y DE UN BETA-BLOQUEANTE
ATE512185T1 (de) Heterobifunktionelle polyethylenglycol-reagenzien
GT200600522A (es) Nueva asociación de un inhibidor de la corriente sinusal i, y de un inhibidor de la enzima de conversión y las composiciones farmacéuticas que la contienen
PH12012501273A1 (en) Oral care compositions and methods
AU2015201137B2 (en) Compositions and method for tissue preservation

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)